$0.81
5.22% yesterday
Nasdaq, May 20, 10:09 pm CET
ISIN
US67577C1053
Symbol
OCGN
Sector
Industry

Ocugen Inc Stock price

$0.81
+0.13 19.63% 1M
-0.11 11.81% 6M
+0.01 0.62% YTD
-1.11 57.81% 1Y
-1.42 63.68% 3Y
+0.50 161.29% 5Y
-476.19 99.83% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.04 5.22%
ISIN
US67577C1053
Symbol
OCGN
Sector
Industry

Key metrics

Market capitalization $236.55m
Enterprise Value $230.57m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 51.01
P/S ratio (TTM) P/S ratio 52.33
P/B ratio (TTM) P/B ratio 14.87
Revenue growth (TTM) Revenue growth 86.63%
Revenue (TTM) Revenue $4.52m
EBIT (operating result TTM) EBIT $-57.04m
Free Cash Flow (TTM) Free Cash Flow $-51.95m
Cash position $37.80m
EPS (TTM) EPS $-0.19
P/E forward negative
P/S forward 93.86
EV/Sales forward 91.49
Short interest 23.76%
Show more

Is Ocugen Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Ocugen Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Ocugen Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Ocugen Inc forecast:

Buy
100%

Financial data from Ocugen Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
4.52 4.52
87% 87%
100%
- Direct Costs 2.70 2.70
221% 221%
60%
1.82 1.82
15% 15%
40%
- Selling and Administrative Expenses 21 21
26% 26%
472%
- Research and Development Expense 35 35
0% 0%
771%
-54 -54
12% 12%
-1,202%
- Depreciation and Amortization 2.70 2.70
221% 221%
60%
EBIT (Operating Income) EBIT -57 -57
9% 9%
-1,262%
Net Profit -57 -57
4% 4%
-1,272%

In millions USD.

Don't miss a Thing! We will send you all news about Ocugen Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocugen Inc Stock News

Neutral
Seeking Alpha
12 days ago
Call Start: 8:30 January 1, 0000 8:59 AM ET Ocugen, Inc. (NASDAQ:OCGN ) Q1 2025 - Earnings Conference Call May 9, 2025, 8:00 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Ramesh Ramachandran - Chief Accounting Officer Huma Qamar - Chief Medical Officer Arun Upadhyay - Chief Scientific Office Confere...
Neutral
GlobeNewsWire
12 days ago
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026 Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025 MALVERN, Pa.
Neutral
GlobeNewsWire
19 days ago
MALVERN, Pa., May 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's first quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, May 9, 2025.
More Ocugen Inc News

Company Profile

Ocugen, Inc. engages in the development and commercialization of therapies for eye diseases. Its pipeline includes OCU400, OCU410, OCU200, OCU200, and OCU300. The company was founded by Shankar Musunuri and Uday Kompella in 2013 and is headquartered in Malvern, PA.

Head office United States
CEO Shankar Musunuri
Employees 95
Founded 2013
Website www.ocugen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today